Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.

Caputo R, Cazzaniga ME, Sbrana A, Torrisi R, Paris I, Giordano M, Montesarchio V, Guarneri V, Amaducci L, Bilancia D, Cilenti G, Fabi A, Collovà E, Schirone A, Bonizzoni E, Celio L, De Placido S, De Laurentiis M.

BMC Cancer. 2020 Mar 19;20(1):232. doi: 10.1186/s12885-020-6707-9.

2.

Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.

Masci G, Agostinetto E, Giordano L, Bottai G, Torrisi R, Losurdo A, De Sanctis R, Navarria P, Scorsetti M, Zuradelli M, de Rose F, Bello L, Santoro A.

Future Oncol. 2020 Mar;16(7):269-279. doi: 10.2217/fon-2019-0602. Epub 2020 Feb 11.

PMID:
32043375
3.

Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction.

De Rose F, Fogliata A, Franceschini D, Cozzi S, Iftode C, Stravato A, Tomatis S, Masci G, Torrisi R, Testori A, Tinterri C, Lisa AVE, Maione L, Vinci V, Klinger M, Santoro A, Scorsetti M.

Med Oncol. 2019 Apr 25;36(6):48. doi: 10.1007/s12032-019-1275-z.

PMID:
31028487
4.

PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.

Antunovic L, De Sanctis R, Cozzi L, Kirienko M, Sagona A, Torrisi R, Tinterri C, Santoro A, Chiti A, Zelic R, Sollini M.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1468-1477. doi: 10.1007/s00259-019-04313-8. Epub 2019 Mar 26.

PMID:
30915523
5.

Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?

Torrisi R, Zuradelli M, Agostinetto E, Masci G, Losurdo A, De Sanctis R, Santoro A.

Crit Rev Oncol Hematol. 2019 Mar;135:66-75. doi: 10.1016/j.critrevonc.2019.01.016. Epub 2019 Jan 30. Review.

PMID:
30819448
6.

EEG recording during an emotional face-matching task in children of mothers with interpersonal violence-related posttraumatic stress disorder.

Perizzolo VC, Berchio C, Moser DA, Gomez CP, Vital M, Arnautovic E, Torrisi R, Serpa SR, Michel CM, Schechter DS.

Psychiatry Res Neuroimaging. 2019 Jan 30;283:34-44. doi: 10.1016/j.pscychresns.2018.11.010. Epub 2018 Nov 29.

PMID:
30530040
7.

Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature.

De Rose F, Fogliata A, Franceschini D, Iftode C, Navarria P, Comito T, Franzese C, Fernandes B, Masci G, Torrisi R, Tinterri C, Testori A, Santoro A, Scorsetti M.

Breast. 2018 Dec;42:31-37. doi: 10.1016/j.breast.2018.08.098. Epub 2018 Aug 22. Review.

PMID:
30149235
8.

Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.

De Sanctis R, Agostinetto E, Masci G, Ferraro E, Losurdo A, Viganò A, Antunovic L, Zuradelli M, Torrisi RMC, Santoro A.

Oncology. 2018;94 Suppl 1:19-28. doi: 10.1159/000489065. Epub 2018 Jul 23.

9.

Developmental delay in communication among toddlers and its relationship to caregiving behavior among violence-exposed, posttraumatically stressed mothers.

Torrisi R, Arnautovic E, Pointet Perizzolo VC, Vital M, Manini A, Suardi F, Gex-Fabry M, Rusconi Serpa S, Schechter DS.

Res Dev Disabil. 2018 Nov;82:67-78. doi: 10.1016/j.ridd.2018.04.008. Epub 2018 May 10.

PMID:
29754762
10.

Never too old to fight breast cancer: A case report.

Zuradelli M, Masci G, Ferraro E, Losurdo A, De Sanctis R, Torrisi R, Santoro A.

Medicine (Baltimore). 2018 Mar;97(9):e9981. doi: 10.1097/MD.0000000000009981.

11.

Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series.

De Rose F, Fogliata A, Franceschini D, Iftode C, Torrisi R, Masci G, Sagona A, Tinterri C, Testori A, Gatzemeier W, Fernandes B, Rahal D, Cozzi L, Santoro A, Scorsetti M.

Br J Radiol. 2018 May;91(1085):20170634. doi: 10.1259/bjr.20170634. Epub 2018 Mar 20.

12.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

13.

The role of SBRT in oligometastatic patients with liver metastases from breast cancer.

Scorsetti M, Franceschini D, De Rose F, Comito T, Franzese C, Masci G, Torrisi R, Viganò L, Torzilli G.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):163-169. doi: 10.1016/j.rpor.2016.07.008. Epub 2016 Sep 5.

14.

Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature.

Losurdo A, Rota S, Gullo G, Masci G, Torrisi R, Bottai G, Zuradelli M, Gatzemeier W, Santoro A.

Crit Rev Oncol Hematol. 2017 May;113:283-291. doi: 10.1016/j.critrevonc.2017.03.013. Epub 2017 Mar 29. Review.

PMID:
28427518
15.

Effects of interpersonal violence-related post-traumatic stress disorder (PTSD) on mother and child diurnal cortisol rhythm and cortisol reactivity to a laboratory stressor involving separation.

Cordero MI, Moser DA, Manini A, Suardi F, Sancho-Rossignol A, Torrisi R, Rossier MF, Ansermet F, Dayer AG, Rusconi-Serpa S, Schechter DS.

Horm Behav. 2017 Apr;90:15-24. doi: 10.1016/j.yhbeh.2017.02.007. Epub 2017 Feb 20.

PMID:
28189641
16.

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.

Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C, Torrisi R, Reis-Filho JS, Roncalli M, Sotiriou C, Santoro A, Mantovani A, Loi S, Santarpia L.

Breast Cancer Res. 2016 Dec 3;18(1):121.

17.

Aromatase inhibitors in premenopause: Great expectations fulfilled?

Torrisi R, Rota S, Losurdo A, Zuradelli M, Masci G, Santoro A.

Crit Rev Oncol Hematol. 2016 Nov;107:82-89. doi: 10.1016/j.critrevonc.2016.08.009. Epub 2016 Aug 28. Review.

PMID:
27823654
18.

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.

Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A.

Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. doi: 10.1158/1940-6207.CAPR-15-0345. Epub 2016 Apr 4.

19.

Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer.

Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, Navarria P, D'Agostino GR, Masci G, Torrisi R, Testori A, Tinterri C, Santoro A.

Breast. 2016 Apr;26:11-7. doi: 10.1016/j.breast.2015.12.002. Epub 2016 Jan 3.

PMID:
27017237
20.

Attitudes on fertility issues in breast cancer patients: an Italian survey.

Biglia N, Torrisi R, D'Alonzo M, Codacci Pisanelli G, Rota S, Peccatori FA.

Gynecol Endocrinol. 2015 Jun;31(6):458-64. doi: 10.3109/09513590.2014.1003293. Epub 2015 May 18.

21.

Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series.

Masci G, Caruso M, Caruso F, Salvini P, Carnaghi C, Giordano L, Miserocchi V, Losurdo A, Zuradelli M, Torrisi R, Di Tommaso L, Tinterri C, Testori A, Garcia-Etienne CA, Gatzemeier W, Santoro A.

Oncologist. 2015 Jun;20(6):586-92. doi: 10.1634/theoncologist.2014-0243. Epub 2015 May 6.

22.

[Traumatic events and stress responses: the role of oxytocin and attachment].

Torrisi R, Pierrehumbert B, Halfon O.

Rev Med Suisse. 2013 Sep 18;9(398):1678-81. French.

PMID:
24164018
23.

Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer.

Masci G, Gandini C, Zuradelli M, Losurdo A, Torrisi R, Rota S, Gullo G, Velutti L, Giordano L, Santoro A.

Anticancer Res. 2013 Oct;33(10):4603-9.

PMID:
24123037
24.

Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.

Torrisi R, Garcia-Etienne CA, Losurdo A, Morenghi E, Di Tommaso L, Gatzemeier W, Sagona A, Fernandes B, Rossetti C, Eboli M, Rubino A, Barbieri E, Andreoli C, Orefice S, Gandini C, Rota S, Zuradelli M, Masci G, Santoro A, Tinterri C.

Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3.

PMID:
23643803
25.

Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit.

Masci G, Losurdo A, Gandini C, Garassino I, di Tommaso L, Torrisi R, Zuradelli M, Santoro A.

Ecancermedicalscience. 2012;6:275. doi: 10.3332/ecancer.2012.275. Epub 2012 Oct 18.

26.

Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.

Scorsetti M, Alongi F, Fogliata A, Pentimalli S, Navarria P, Lobefalo F, Garcia-Etienne C, Clivio A, Cozzi L, Mancosu P, Nicolini G, Vanetti E, Eboli M, Rossetti C, Rubino A, Sagona A, Arcangeli S, Gatzemeier W, Masci G, Torrisi R, Testori A, Alloisio M, Santoro A, Tinterri C.

Radiat Oncol. 2012 Aug 28;7:145. doi: 10.1186/1748-717X-7-145.

27.

Adult attachment representations predict cortisol and oxytocin responses to stress.

Pierrehumbert B, Torrisi R, Ansermet F, Borghini A, Halfon O.

Attach Hum Dev. 2012;14(5):453-76. doi: 10.1080/14616734.2012.706394.

PMID:
22856618
28.

Endocrine response and perceived stress test during an experimental challenge task in adult survivors of a childhood cancer.

Laufer D, Ansermet F, von der Weid N, Beck Popovic M, Torrisi R, Pierrehumbert B.

Pediatr Blood Cancer. 2012 Jul 15;59(1):138-43. doi: 10.1002/pbc.24044. Epub 2011 Dec 20.

PMID:
22190475
29.

Fulvestrant for advanced male breast cancer patients: a case series.

Masci G, Gandini C, Zuradelli M, Pedrazzoli P, Torrisi R, Lutman FR, Santoro A.

Ann Oncol. 2011 Apr;22(4):985. doi: 10.1093/annonc/mdr005. No abstract available.

30.

Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer.

Dellapasqua S, Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, Maisonneuve P, Viale G, Cassano E, Veronesi P, Luini A, Goldhirsch A, Colleoni M.

Breast. 2011 Aug;20(4):319-23. doi: 10.1016/j.breast.2011.02.014. Epub 2011 Mar 11.

31.

Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.

Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida M, Veronesi P, Luini A, Viale G, Santoro A, Colleoni M, Goldhirsch A.

Breast Cancer Res Treat. 2011 Apr;126(2):431-41. doi: 10.1007/s10549-010-1340-y. Epub 2011 Jan 8.

PMID:
21221766
32.

Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.

Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Clin Breast Cancer. 2010 Dec 1;10(6):483-8. doi: 10.3816/CBC.2010.n.064.

PMID:
21147693
33.

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM.

J Clin Oncol. 2010 Sep 1;28(25):3910-6. doi: 10.1200/JCO.2009.27.3615. Epub 2010 Aug 2.

PMID:
20679614
34.

Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.

Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16.

35.

A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.

Colleoni M, Bagnardi V, Rotmensz N, Viale G, Mastropasqua M, Veronesi P, Cardillo A, Torrisi R, Luini A, Goldhirsch A.

Eur J Cancer. 2010 Aug;46(12):2216-24. doi: 10.1016/j.ejca.2010.04.008. Epub 2010 May 13.

PMID:
20471822
36.

Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M.

Ann Oncol. 2010 Oct;21(10):1974-81. doi: 10.1093/annonc/mdq072. Epub 2010 Mar 23.

37.

Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.

Rocca A, Cancello G, Bagnardi V, Sandri MT, Torrisi R, Zorzino L, Viale G, Pietri E, Veronesi P, Dellapasqua S, Ferrucci F, Luini A, Johansson H, Ghisini R, Goldhirsch A, Colleoni M.

Anticancer Res. 2009 Dec;29(12):5111-9.

38.

Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.

Montagna E, Cancello G, Torrisi R, Rizzo S, Scarano E, Colleoni M.

Ann Oncol. 2010 Mar;21(3):667-8. doi: 10.1093/annonc/mdp563. Epub 2009 Dec 23. No abstract available.

39.

Oxytocin response to an experimental psychosocial challenge in adults exposed to traumatic experiences during childhood or adolescence.

Pierrehumbert B, Torrisi R, Laufer D, Halfon O, Ansermet F, Beck Popovic M.

Neuroscience. 2010 Mar 10;166(1):168-77. doi: 10.1016/j.neuroscience.2009.12.016. Epub 2009 Dec 16.

PMID:
20018229
40.

Closeness in relationships as a mediator between sexual abuse in childhood or adolescence and psychopathological outcome in adulthood.

Dimitrova N, Pierrehumbert B, Glatz N, Torrisi R, Heinrichs M, Halfon O, Chouchena O.

Clin Psychol Psychother. 2010 May-Jun;17(3):183-95. doi: 10.1002/cpp.650.

PMID:
19757501
41.

Preoperative chemo- and endocrine therapy.

Torrisi R.

Cancer Treat Res. 2009;151:103-20. doi: 10.1007/978-0-387-75115-3_8. Review. No abstract available.

PMID:
19593509
42.

Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure.

Montagna E, Viale G, Rotmensz N, Maisonneuve P, Galimberti V, Luini A, Intra M, Veronesi P, Mazzarol G, Pruneri G, Renne G, Torrisi R, Cardillo A, Cancello G, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2009 Nov;118(2):385-94. doi: 10.1007/s10549-009-0446-6. Epub 2009 Jun 27.

PMID:
19562480
43.

A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer.

Colleoni M, Bagnardi V, Rotmensz N, Dellapasqua S, Viale G, Pruneri G, Veronesi P, Torrisi R, Luini A, Intra M, Galimberti V, Montagna E, Goldhirsch A.

Ann Oncol. 2009 Jul;20(7):1178-84. doi: 10.1093/annonc/mdn747. Epub 2009 Feb 13.

44.

The influence of attachment on perceived stress and cortisol response to acute stress in women sexually abused in childhood or adolescence.

Pierrehumbert B, Torrisi R, Glatz N, Dimitrova N, Heinrichs M, Halfon O.

Psychoneuroendocrinology. 2009 Jul;34(6):924-38. doi: 10.1016/j.psyneuen.2009.01.006. Epub 2009 Feb 12.

PMID:
19217212
45.

Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.

Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Bertolini F, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M.

Anticancer Drugs. 2009 Mar;20(3):197-203. doi: 10.1097/CAD.0b013e3283264719.

PMID:
19182679
46.

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.

Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A.

Breast Cancer Res Treat. 2009 Jul;116(2):359-69. doi: 10.1007/s10549-008-0223-y. Epub 2008 Oct 22.

PMID:
18941889
47.

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.

Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M.

Br J Cancer. 2008 Nov 18;99(10):1564-71. doi: 10.1038/sj.bjc.6604741. Epub 2008 Oct 21.

48.

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.

Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, Intra M, Torrisi R, Cardillo A, Campagnoli E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2009 Jul;116(2):317-28. doi: 10.1007/s10549-008-0206-z. Epub 2008 Oct 7.

PMID:
18839307
49.

Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.

D'Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, Balduzzi A, Scarano E, Ghisini R, Peruzzotti G, Goldhirsch A, Colleoni M.

Breast J. 2008 Sep-Oct;14(5):435-41. doi: 10.1111/j.1524-4741.2008.00619.x.

PMID:
18821931
50.

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M.

J Clin Oncol. 2008 Oct 20;26(30):4899-905. doi: 10.1200/JCO.2008.17.4789. Epub 2008 Sep 15.

PMID:
18794539

Supplemental Content

Loading ...
Support Center